A panelist discusses how demodex blepharitis frequently co-occurs with other ocular surface conditions in younger patients, as illustrated by a 35-year-old contact lens wearer who presented with recurrent styes, contact lens intolerance, and a history of rosacea.
A panelist discusses how treating ocular surface disease and demodex blepharitis before cataract surgery led to improved refractive measurements, resolved corneal staining, and enabled successful multifocal IOL implantation in a patient who had previously shown irregularly irregular topography patterns.
A panelist discusses how demodex blepharitis presents with distinctive symptoms like eyelash itching, colorettes at the base of lashes, and can significantly affect pre-surgical cataract measurements, requiring treatment before proceeding with surgery.
At the 2025 ASCRS meeting, Dr. Sarkisian presented 3-year data on the iDose TR from the FDA clinical trial.
Dilsher S. Dhoot, MD, discusses how second-generation anti-VEGF agents like aflibercept 8 mg and faricimab demonstrate significant efficacy in treating diabetic macular edema (DME), allowing for extended treatment intervals of 9 to 10 weeks compared to monthly dosing with earlier agents, while improving anatomic outcomes and visual acuity.
Dilsher S. Dhoot, MD, discusses how newer anti-VEGF treatments, particularly aflibercept 8 mg, can provide improved anatomic outcomes and extended treatment intervals for patients with neovascular age-related macular degeneration who show persistent subretinal fluid despite treatment with first-generation agents.
Two FDA-approved geographic atrophy treatments show significant patient dropout, with 45% discontinuation by 18 months, driven by baseline vision, CNV, and lack of immediate visual improvement.
At ARVO 2025, in Salt Lake City, Utah, Emma Lessieur-Contreras, MD, PhD, talked about her poster on retina extracellular vesicles, and the role that they play on diabetic retinopathy.
Deep Parikh, MD, sat down with Emily Kaiser Maharjan from Optometry Times to talk about his presentation at Collaborative Care Symposium on advanced treatments in neovascular retinal disease.
At ARVO 2025, in Salt Lake City, Utah, Carly Lam, PhD, MSc, and Tsz Wing Leung, PhD talked about the evaluation of the visual performance of 2 modified DIMS spectacle lens designs.
Investigators were surprised by the outcome of a comparison between the Eyhance and enVista IOLs in low-light conditions.
Lori Wright, JD, sat down to talk about a discussion at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.
Early improvements in OSDI scores and tear osmolarity reinforce lifitegrast’s role in managing inflammation-driven dry eye disease.
At ARVO 2025, in Salt Lake City, Utah, Dilsher Dhoot, MD, FASRS, and Mark Barakat, MD, talked about the PHOTON trial, 8 mg versus 2 mg during the matched dosing phase, and outcomes of shortened, maintained, or extended dosing intervals
Ophthalmologist Dilraj Grewal explores cutting-edge clinical trials for uveitis treatment, highlighting new targeted therapies that aim to control inflammation and macular edema with fewer steroid-related side effects.
Lexitas Pharma Services' CMO discusses groundbreaking ophthalmology conference, emphasizing innovative clinical trials, emerging treatments for eye diseases, and the potential for transformative patient care strategies.
A conversation with David S. Friedman, MD, PhD, on treating uncontrolled open-angle glaucoma in patients with limited options
A significant proportion of cataract surgery patients exhibit hyperosmolar tear film both before and 1 month after surgery, underscoring preoperative screening and postoperative management to optimize visual outcomes.
At the Retina World Congress, we spoke with Siegfried Priglinger, MD, about ensuring the best outcomes for preschool-aged patients
A panelist discusses how he managed a 57-year-old tennis player with dry eye and Hashimoto thyroiditis by selecting a Toric enVista IOL for her refractive lens exchange, noting the patient’s satisfaction despite a temporary market recall of the lens.
A panelist discusses how he successfully treated a complex case of a 72-year-old patient with previous radial keratotomy by using an innovative combination of an Apthera lens in the bag and a light adjustable lens in the sulcus as a primary piggyback.
A panelist discusses how ophthalmologists face challenges with Generation X patients who desire spectacle independence after laser vision correction, highlighting the difficulties in intraocular lens calculations and epithelial irregularities following previous refractive surgeries.
At ARVO 2025, in Salt Lake City, Utah, Steven Barnes, PhD, talked about his research on the OPA1 mutation in retinal ganglion cells' effect on the cell's electrical function.
At ARVO 2025, in Salt Lake City, Utah, Hsin-Yu Yang talked about the 9-month results from her study on the effectiveness of DIMS spectral lenses in myopic retardation for the pre-myopic preschoolers in Taiwan.
At ARVO 2025, in Salt Lake City, Utah, Alex Choi discussed his poster on APOE carrier genetic status and its relation to Alzheimer disease as well as changes of the retina that might reflect early signs leading to an earlier diagnosis of the disease
Steven Greenstein, MD, one of the cochairs of the Collaborative Care Symposium gave some insight into the upcoming conference and what attendees can expect.
